competition – Page 5

European Commission Grants Approval for Illumina to Divest Grail

2 years ago talkbio0Tagged Antitrust, competition, Divestment, European Commission, Illumina

Illumina, Grail, European Commission, Divestment, Competition, Antitrust

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

2 years ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials

Bayer Prepares Menopause Drug Rival to Astellas’ Veozah for Regulatory Filings Following Successful Phase 3 Trials

2 years ago talkbio0Tagged Astellas, Bayer, competition, Elinzanetant, Menopause, regulatory approval, Veozah

Bayer, Menopause Drug, Elinzanetant, Phase 3 Hat Trick, Regulatory Approval, Competition with Astellas’ Veozah

Bayer’s Menopause Drug Elinzanetant Achieves Successful Long-Term Results in Phase III Trial, Rivalling Astellas’ Veozah

2 years ago talkbio0Tagged Astellas, Bayer, competition, Elinzanetant, Hot flushes, Long-term, Menopause, Phase 3 Clinical Trials, vasomotor symptom, Veozah

Bayer, Elinzanetant, Menopause drug, Phase III trial, Long-term results, Hot flashes, Vasomotor symptoms, Astellas, Veozah, Competition

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

2 years ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies